In many tumour types serumlactate dehydrogenase (LDH) levels proved to represent an indirect marker of tumour hypoxia, neo-angiogenesis and worse prognosis. As we previously reported LDH is an important predictive factor in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). Sorafenib represents the therapeutic stronghold in advanced HCC patients. As a tyrosine kinase inhibitor (TKI) mainly directed against the angiogenetic pathway, the correlation of sorafenib administration with markers of hypoxia could be an important tool in patients management. Aim of our analysis was to evaluate the role of LDH pre-treatment levels and its variation during treatment in HCC patients receiving sorafenib.

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management / Faloppi, Luca; Scartozzi, Mario; Bianconi, Maristella; Svegliati Baroni, Gianluca; Toniutto, Pierluigi; Giampieri, Riccardo; Del Prete, Michela; De Minicis, Samuele; Bitetto, Davide; Loretelli, Cristian; D'Anzeo, Marco; Benedetti, Antonio; Cascinu, Stefano. - In: BMC CANCER. - ISSN 1471-2407. - 14:1(2014), pp. 110-118. [10.1186/1471-2407-14-110]

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management

CASCINU, Stefano
2014

Abstract

In many tumour types serumlactate dehydrogenase (LDH) levels proved to represent an indirect marker of tumour hypoxia, neo-angiogenesis and worse prognosis. As we previously reported LDH is an important predictive factor in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). Sorafenib represents the therapeutic stronghold in advanced HCC patients. As a tyrosine kinase inhibitor (TKI) mainly directed against the angiogenetic pathway, the correlation of sorafenib administration with markers of hypoxia could be an important tool in patients management. Aim of our analysis was to evaluate the role of LDH pre-treatment levels and its variation during treatment in HCC patients receiving sorafenib.
14
1
110
118
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management / Faloppi, Luca; Scartozzi, Mario; Bianconi, Maristella; Svegliati Baroni, Gianluca; Toniutto, Pierluigi; Giampieri, Riccardo; Del Prete, Michela; De Minicis, Samuele; Bitetto, Davide; Loretelli, Cristian; D'Anzeo, Marco; Benedetti, Antonio; Cascinu, Stefano. - In: BMC CANCER. - ISSN 1471-2407. - 14:1(2014), pp. 110-118. [10.1186/1471-2407-14-110]
Faloppi, Luca; Scartozzi, Mario; Bianconi, Maristella; Svegliati Baroni, Gianluca; Toniutto, Pierluigi; Giampieri, Riccardo; Del Prete, Michela; De Minicis, Samuele; Bitetto, Davide; Loretelli, Cristian; D'Anzeo, Marco; Benedetti, Antonio; Cascinu, Stefano
File in questo prodotto:
File Dimensione Formato  
1471-2407-14-110.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 477.94 kB
Formato Adobe PDF
477.94 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1079089
Citazioni
  • ???jsp.display-item.citation.pmc??? 35
  • Scopus 68
  • ???jsp.display-item.citation.isi??? 68
social impact